Advicenne
Paris
About Advicenne
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $49.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: epa:ADVIC
- Website: advicenne.com
- Phone: +33 (0)1 85 73 36 20
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/advicenne-48036 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.